financetom
Business
financetom
/
Business
/
BRIEF-Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
Aug 1, 2025 4:19 AM

Aug 1 (Reuters) - Arrowhead Pharmaceuticals Inc ( ARWR )

:

* ARROWHEAD SUBSIDIARY VISIRNA SELLS RIGHTS TO

HYPERTRIGLYCERIDEMIA CANDIDATE PLOZASIRAN IN GREATER CHINA TO

SANOFI

* ARROWHEAD PHARMACEUTICALS INC ( ARWR ) - SANOFI TO PAY $130 MILLION

UPFRONT, $265 MILLION IN MILESTONES

* ARROWHEAD PHARMACEUTICALS INC ( ARWR ) - SANOFI RECEIVES EXCLUSIVE

LICENSE FOR PLOZASIRAN IN CHINA

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved